HyTest | SARS-Cov-2重組抗原和血清學標記產品介紹

HyTest COVID-19 News

新冠病毒SARS-Cov-2重組抗原–提供R＆D樣品

We are finalizing the development of SARS-Cov-2 Spike RBD recombinant antigen. The antigen is produced in mammalian cells and could be used in serology assays. 

The product is lyophilized, which makes its shipment and storage convenient.

We now have a limited amount of R&D samples available.

While IgA has gained little attention by developers of SARS-Cov-2 antibody tests, recent publications suggest that including it in serology assays could improve the sensitivity of the tests.

It was shown that IgA antibodies can be detected earlier than IgM or IgG antibodies. Also, IgA (and IgG) antibodies seem to positively correlate with the severity of the disease.

Webinar Video COVID-19: Biomarkers to Distinguish Severity and Prognosis  

By watching this webinar, you will learn about:

-  the use of nucleic acid testing and serological testing for diagnostics of COVID-19, as well as the benefits and limitations of these methods for COVID-19 diagnostics

-  the effects of SARS-CoV-2 on the cardiovascular system

-  the role of cardiac and inflammatory biomarkers in distinguishing the severity and prognosis of COVID-19